证券代码：605266 证券简称：健之佳 公告编号：2025-054 健之佳医药连锁集团股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 10 月 30 日 （星期四） 10:00-11:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 10 月 24 日 （星期五） 至 10 月 29 日 （星期三） 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@jzj.cn 进行提问；或在 2025 年 10 月 30 日（星期四）10:00-11:00，通过互 联网登录上证路演中心（https://roadshow.sseinfo.com/），在线参与本次业绩 说明会。公司将在说明会上对投资者普遍关注的问题进行回答。 一、 说 ...

Market Overview - The pharmaceutical commercial sector increased by 0.55% on October 21, with First Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3916.33, up 1.36%, while the Shenzhen Component Index closed at 13077.32, up 2.06% [1] Stock Performance - First Pharmaceutical (600833) closed at 13.64, up 2.48% with a trading volume of 58,500 shares and a transaction value of 79.03 million yuan [1] - Other notable performers included: - Haiwang Biological (000078) at 2.55, up 2.41% [1] - HeFu China (603122) at 6.55, up 2.34% [1] - Ruikang Pharmaceutical (002589) at 2.93, up 2.09% [1] - Daclin (603233) at 18.67, up 1.52% with a transaction value of 293 million yuan [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 105 million yuan from institutional investors and 110 million yuan from speculative funds, while retail investors saw a net inflow of 215 million yuan [2] - The capital flow for individual stocks showed mixed results, with China Pharmaceutical (600056) seeing a net inflow of 28.32 million yuan from institutional investors [3] Individual Stock Capital Flow - Key stocks with significant capital flow include: - China Pharmaceutical (600056) with a net inflow of 28.32 million yuan from institutional investors [3] - Jiuzhoutong (600998) with a net inflow of 24.77 million yuan from institutional investors [3] - Shanghai Pharmaceutical (601607) with a net inflow of 11.37 million yuan from institutional investors [3]

Core Points - The company has completed the registration of changes in business scope and has obtained a new business license from the Yunnan Provincial Market Supervision Administration [1][2][3] - The changes include the addition of "sales of sanitary insecticides" and "pet services (excluding animal diagnosis)" to the company's business scope [1] - The company's governance structure has been adjusted by canceling the supervisory board and setting up employee directors, along with amendments to the Articles of Association [1]

证券代码：605266 证券简称：健之佳 公告编号：2025-053 健之佳医药连锁集团股份有限公司 关于完成工商变更登记并换发营业执照的公告 近日，公司完成了增加经营范围的工商变更登记及修订《公司章程》的工商 备案手续，并取得云南省市场监督管理局换发的《营业执照》。 《营业执照》变更登记信息如下： 公司经营范围新增"卫生用杀虫剂销售；宠物服务（不含动物诊疗）"。 《营业执照》中除经营范围外的其余登记内容未变更。 特此公告。 健之佳医药连锁集团股份有限公司董事会 2025年10月11日 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据健之佳医药连锁集团股份有限公司（以下简称"公司"）2025年第一次 临时股东会审议通过的《关于取消监事会、设置职工董事并修订<公司章程>及附 件的议案》，根据法律法规的规定及公司实际，拟调整公司治理架构，同时变更 经营范围，对《公司章程》的相关内容进行修订和完善，办理工商变更登记。具 体内容详见公司于2025年8月29日在上海证券交易所网站（www.sse.com.cn）披 露的《关于取消 ...

Core Viewpoint - The actual controller's associated party, Ms. Lan Xinyue, has increased her shareholding in the company, indicating confidence in the company's future performance [1] Group 1: Shareholding Increase - Ms. Lan Xinyue acquired 68,600 shares from July 10, 2025, to October 9, 2025, representing 0.04% of the company's total share capital [1] - After the acquisition, Ms. Lan Xinyue holds a total of 200,000 shares, which is 0.13% of the company's total share capital [1] - The total transaction amount for the share purchase was 1.4452 million yuan [1]

北京德恒（昆明）律师事务所 关于健之佳医药连锁集团股份有限公司 实际控制人之一致行动人增持公司股份的 专项核查意见 北京德恒（昆明）律师事务所 Beijing DeHeng Law Offices (KunMing) 云南省昆明市西山区西园路 126 号"融城优郡"B5 幢 3-4 层 电话:0871-63172192 传真: 0871-63172192 邮编: 650032 北京德恒(昆明)律师事务所 关于健之佳医药连锁集团股份有限公司 实际控制人之一致行动人增持公司股份的专项核查意见 录 目 | 释 | | --- | | 正 文 | | 一、增持人的主体资格…………………………………………… | | 二、本次增持的具体情况 | | 三、本次增持的信息披露 | | 四、本次增持属于《收购管理办法》规定的免于发出要约的情形………………………………………………………………………… | | 五、结论意见 . | 关于健之佳医药连锁集团股份有限公司 北京德恒（昆明）律师事务所 实际控制人之一致行动人增持公司股份的专项核查意见 释 义 本核查意见中，除非文中另有所指，下列简称具有如下特定含义： | 公司、健之佳 | ...

证券代码：605266 证券简称：健之佳 公告编号：2025-052 健之佳医药连锁集团股份有限公司 关于实际控制人之一致行动人增持计划实施完毕暨增持结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次增持计划前，增持主体持有公司股份情况： 健之佳医药连锁集团股份有限公司（以下简称"公司"）实际控制人蓝波、 舒畅夫妇的一致行动人蓝心悦女士于 2025 年 7 月 7 日前持有公司股份 100,000 股，占公司总股本的 0.0647%。 蓝心悦女士于 2025 年 7 月 7 日-9 日期间通过上海证券交易所交易系统以集 中竞价方式增持公司股份 31,400 股，占公司总股本的 0.0203%，该次增持后， 蓝心悦女士持有公司股份 131,400 股，占公司总股本的 0.0850%。具体内容详见 公司于 2025 年 7 月 10 日在上海证券交易所网站披露的《关于实际控制人之一致 行动人增持公司股份及后续增持计划的公告》（公告编号：2025-039）。 已披露的本次增持计划情况： 本的 0 ...

Core Points - The actual controllers of the company, Lan Bo and Shu Chang, along with their concerted actor, Lan Xin Yue, have completed a share buyback plan [1] - From July 11, 2025, to September 25, 2025, they purchased a total of 68,600 shares, representing 0.0444% of the company's total share capital, for a transaction amount of 1.4452 million yuan [1] - After the buyback, Lan Xin Yue holds 200,000 shares, which is 0.1294% of the total share capital, while the combined holdings of Lan Bo, Shu Chang, and their concerted actors amount to 63.0076 million shares, or 40.7703% of the total share capital [1]

Core Viewpoint - The company reported stable revenue with a significant improvement in profit, driven by effective cost control and a low base from the previous year [1][3]. Financial Performance - In 1H25, the company achieved revenue of 4.46 billion yuan, a slight decrease of 0.6% year-on-year, while net profit attributable to shareholders was 70 million yuan, an increase of 15.1% year-on-year [1]. - In Q2 25, revenue was 2.16 billion yuan, down 0.4% year-on-year and down 5.7% quarter-on-quarter, with net profit attributable to shareholders reaching 40 million yuan, up 265.9% year-on-year and up 15.9% quarter-on-quarter [1]. - The company’s gross profit margin for 1H25 was 35.7%, a decrease of 0.2 percentage points year-on-year, while the net profit margin was 1.6%, an increase of 0.2 percentage points year-on-year [3]. Operational Adjustments - The company adjusted its store expansion strategy, focusing on improving existing stores amid industry consolidation, resulting in a net decrease of 22 stores to a total of 5,464 stores by the end of 1H25 [2]. - The revenue from the pharmaceutical retail business in 1H25 was 4.02 billion yuan, down 0.4% year-on-year, with a gross margin of 35.0%, an increase of 0.1 percentage points year-on-year [2]. Product Performance - Prescription drug revenue was 1.47 billion yuan, down 6.7% year-on-year, while non-prescription drug revenue increased by 3.9% to 1.76 billion yuan [2]. - The revenue from traditional Chinese medicine was 150 million yuan, down 11.7% year-on-year, and medical device revenue was 330 million yuan, up 5.1% year-on-year [2]. Cash Flow and Cost Management - The net cash flow from operating activities in 1H25 was 551 million yuan, a significant improvement from 290 million yuan in 1H24 [3]. - The company implemented comprehensive cost control measures, including managing rental, labor, and distribution costs, which contributed to the improved profit margins [1][3]. Investment Outlook - The company is positioned to benefit from ongoing industry consolidation, with adjusted net profit forecasts for 2025-2027 being 170 million, 210 million, and 260 million yuan, reflecting year-on-year growth of 36%, 22%, and 22% respectively [3]. - A target price of 22.5 yuan is set based on a 20x target PE for 2025, maintaining a "recommended" rating [3].

Core Viewpoint - The stock price of Jianzhijia has experienced a decline of 6.47% year-to-date, with significant drops in recent trading days, indicating potential challenges in the company's market performance [2]. Company Overview - Jianzhijia Pharmaceutical Chain Group Co., Ltd. is located in Kunming, Yunnan Province, established on September 27, 2004, and listed on December 1, 2020. The company specializes in the retail of health products, including pharmaceuticals, health foods, personal care items, and daily consumables [2]. - The revenue composition of Jianzhijia includes: prescription and non-prescription drugs (72.60%), with non-prescription drugs at 39.64% and prescription drugs at 32.96%. Other segments include medical devices (7.44%), convenience products (5.05%), health foods (4.84%), and personal care products (1.18%) [2]. Financial Performance - For the first half of 2025, Jianzhijia reported a revenue of 4.457 billion yuan, a year-on-year decrease of 0.64%. However, the net profit attributable to shareholders increased by 15.11% to 72.3782 million yuan [2]. - Since its A-share listing, Jianzhijia has distributed a total of 715 million yuan in dividends, with 473 million yuan distributed over the past three years [3]. Shareholder and Institutional Holdings - As of June 30, 2025, Jianzhijia had 15,100 shareholders, a decrease of 12.99% from the previous period. The average number of circulating shares per shareholder increased by 26.21% to 10,236 shares [2]. - Among the top ten circulating shareholders, Rongtong Health Industry Flexible Allocation Mixed A/B holds 7.1 million shares, a decrease of 294,800 shares from the previous period. Meanwhile, Guangfa Innovation Upgrade Mixed has entered the list as a new shareholder with 1.7029 million shares [4].